The National Institutes of Health (NIH) awarded $129.3 million in contracts for scale-up and manufacturing support for new COVID-19 testing technologies as part of the Rapid Acceleration of Diagnostics (RADx) initiative. The NIH is awarding contracts to nine companies for point-of-care test technologies and high-throughput laboratory tests. Details of the contracts follow.
- MatMaCorp – A portable mini-lab that can rapidly perform multiple RT-PCR assays in a single platform.
- MicroGEM International – A portable, point-of-care device that detects SARS-CoV-2 in saliva samples using RT-PCR in 15 minutes.
- Maxim Biomedical Inc – A single-use, lateral-flow test strip immunoassay that can provide results in 15 minutes or less.
- Aegis Sciences – Increased capacity from 15,000 samples per day to 60,000 samples per day.
- Broad Institute – Increased capacity from 25,000 test per day to 100,000 tests per day.
- Ceres Nanoscience Inc – A sample prep method using Nanotrap particles that extracts and concentrates viral material to reduce processing time and improve sensitivity.
- Illumina – Automated sample processing and next-generation sequencing technology for COVID-19 testing that will be scaled up.
- PathGroup – They have partnered with ThermoFisher, LGC and Illumina to add additional instrumentation and automation to increase the daily number of COVID-19 tests performed to 80,000 by December 2020
- Sonic Healthcare USA – Adding capacity to reach 166,000 samples tested per day.